- Home
- PAM vs ICUI Comparison
PAM vs ICUI Comparison
Compare PAM & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAM | ICUI |
|---|---|---|
| Founded | 1945 | 1984 |
| Country | Argentina | United States |
| Employees | 1847 | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.6B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | PAM | ICUI |
|---|---|---|
| Price | $82.23 | $154.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $94.50 | ★ $169.00 |
| AVG Volume (30 Days) | 188.5K | ★ 289.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 1.20 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | $204,770.38 | N/A |
| Revenue Next Year | $16.65 | $4.46 |
| P/E Ratio | ★ $13.79 | $132.86 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $54.95 | $107.02 |
| 52 Week High | $94.50 | $160.62 |
Technical Indicators
Market Signals| Indicator | PAM | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 65.45 |
| Support Level | $78.83 | $146.59 |
| Resistance Level | $89.86 | $160.09 |
| Average True Range (ATR) | 2.84 | 5.41 |
| MACD | -0.24 | 1.11 |
| Stochastic Oscillator | 34.86 | 73.23 |
Price Performance
Historical ComparisonAbout PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business, mainly in oil and gas production and power generation. The firm's operating business segments are Oil and Gas, Generation, Petrochemicals, Holding, Transportation, and Others. The company derives the maximum revenue from the oil and gas segment.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.